M2 AML: Difference between revisions
No edit summary |
No edit summary |
||
| Line 31: | Line 31: | ||
{{Hematological malignancy histology}} | {{Hematological malignancy histology}} | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
Latest revision as of 19:11, 24 August 2015
| M2 AML | |
| ICD-O: | 9874/3 |
|---|---|
|
WikiDoc Resources for M2 AML |
|
Articles |
|---|
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on M2 AML at Clinical Trials.gov Clinical Trials on M2 AML at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on M2 AML
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Directions to Hospitals Treating M2 AML Risk calculators and risk factors for M2 AML
|
|
Healthcare Provider Resources |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
M2 is a subtype of AML (Acute Myeloid Leukemia).
Pathophysiology
This subtype is characterized by a translocation of a part of chromosome 8 to chromosome 21, written as t(8;21). On both sides of the chromosome, now containing pieces from two chromosomes, the DNA codes for different proteins. These two proteins are now being created as one single large protein, with a different effect in the body as the two proteins originally coded by the two different chromosomes. The two different proteins that are fused together are:
- RUNX1
- ETO